This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wexler, H M Articles by Finegold, S M Search for Related Content PubMed PubMed Citation Articles by Wexler, H M Articles by Finegold, S M

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1992 January; 36(1): 239-243

In vitro activities of three of the newer quinolones against anaerobic bacteria.

H M Wexler, E Molitoris and S M Finegold

Research Service, Veterans Administration Medical Center, West Los Angeles, Wadsworth Division, California 90073.

ABSTRACT

The antimicrobial activities of three new quinolone compounds, sparfloxacin, temafloxacin, and WIN 57273, against anaerobic bacteria were determined in three separate studies. The Wadsworth agar dilution technique using brucella-laked blood agar was used throughout. The activities of other antimicrobial agents, including ciprofloxacin, imipenem, chloramphenicol, metronidazole, cefotetan, cefoxitin, and amoxicillin-clavulanic acid, were also determined. The breakpoints of the new quinolones were 2 micrograms/ml for sparfloxacin and WIN 57273 and 4 micrograms/ml for temafloxacin. WIN 57273 displayed very good activity against anaerobes, inhibiting all strains of Bacteroides fragilis group species at 2 micrograms/ml. Only two strains of Fusobacterium species were resistant (MIC, 4 micrograms/ml). Sparfloxacin inhibited 78% of B. fragilis strains and 44% of other B. fragilis group isolates at 2 micrograms/ml. At 2 micrograms/ml, the percentages of other anaerobic species susceptible were as follows: B. gracilis, 70%; other Bacteroides species, 61%; Clostridium species, 50%; Fusobacterium species, 70%; Peptostreptococcus species, 91%; non-spore-forming gram-positive rods, 71%. Temafloxacin inhibited 91% of B. fragilis strains and 87% of other B. fragilis group species at 4 micrograms/ml. All strains of other Bacteroides species, 78% of Fusobacterium species, 80% of Clostridium species, and 90% of Peptostreptococcus species were inhibited at 4 micrograms of temafloxacin per ml.

---

Antimicrob Agents Chemother. 1992 January; 36(1): 239-243

This article has been cited by other articles:

• Koeth, L. M., Good, C. E., Appelbaum, P. C., Goldstein, E. J. C., Rodloff, A. C., Claros, M., Dubreuil, L. J. (2004). Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 53: 1039-1044 [Abstract] [Full Text]  
• Mirzayan, R., Itamura, J. M., Vangsness, T. Jr., Holtom, P. D., Sherman, R., Patzakis, M. J. (2000). Management of Chronic Deep Infection Following Rotator Cuff Repair. JBJS 82: 1115-1115 [Abstract] [Full Text]  
• Paker, G. E., Graham, J. A., Rauch, A. M., Collins, J. J. (1994). Cefuroxime Axetil in the Treatment of Sinusitis: A Review. Arch Fam Med 3: 165-175 [Abstract]